Life Summary
Lee Dong-ki is the CEO of OliX.

He focuses on developing RNA interference (RNAi) therapeutics that suppress the expression of disease-causing genes and the production of related proteins in advance.

He was born in Busan on January 6, 1972.

After graduating from Gyeongnam Science High School, he earned a bachelor’s degree in chemistry from KAIST (Korea Advanced Institute of Science and Technology). He then received a Ph.D. in biochemistry from Cornell University in the United States.

He worked at POSTECH (Pohang University of Science and Technology) before being appointed as a professor in the Department of Chemistry at Sungkyunkwan University.

In 2010, he founded OliX and has since served concurrently as both a university professor and the company’s CEO.

In 2025, he licensed a candidate substance for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) to the global pharmaceutical company Eli Lilly.

The RNA interference therapeutics under development are drawing attention from the global pharmaceutical and biotech industries for their potential use in treating rare diseases for which no therapies currently exist.

He also founded the Korean Society of Nucleic Acids and served as its vice president.

#OliX #LeeDongki #RNAi #biotech #EliLilly #MASH #genetherapy #biopharmaceuticals #KAIST #SungkyunkwanUniversity